Abstract
There is great heterogeneity in the way humans respond to medications, often requiring empirical strategies to define the appropriate drug therapy for each patient. Genetic polymorphisms in drug metabolizing enzymes, transporters, receptors, and other drug targets provide putative markers for predicting which patients will experience extreme toxicity and treatment failure. Both quantitative (allele frequency) and qualitative (specific allele) differences for polymorphic genes have been observed between different population groups. For example, the frequency of mutations in thiopurine methyltransferase is lower in Chinese than Caucasian populations. In addition, the predominant mutation responsible for deficient enzyme activity differs between the two populations (TPMT*3C versus TPMT*3A). Understanding the influence of ethnicity on pharmacogenomics will allow for comprehensive strategies for using the genome to optimize therapy for patients throughout the world.
Keywords: Pharmacogenetics, Pharmacogenomics, Ethnicity, TPMT, ABCB1, TYMS, VKORC1
Current Drug Targets
Title: Ethnic Differences in Pharmacogenetically Relevant Genes
Volume: 7 Issue: 12
Author(s): R. M. Engen, S. Marsh, D. J. Van Booven and H. L. McLeod
Affiliation:
Keywords: Pharmacogenetics, Pharmacogenomics, Ethnicity, TPMT, ABCB1, TYMS, VKORC1
Abstract: There is great heterogeneity in the way humans respond to medications, often requiring empirical strategies to define the appropriate drug therapy for each patient. Genetic polymorphisms in drug metabolizing enzymes, transporters, receptors, and other drug targets provide putative markers for predicting which patients will experience extreme toxicity and treatment failure. Both quantitative (allele frequency) and qualitative (specific allele) differences for polymorphic genes have been observed between different population groups. For example, the frequency of mutations in thiopurine methyltransferase is lower in Chinese than Caucasian populations. In addition, the predominant mutation responsible for deficient enzyme activity differs between the two populations (TPMT*3C versus TPMT*3A). Understanding the influence of ethnicity on pharmacogenomics will allow for comprehensive strategies for using the genome to optimize therapy for patients throughout the world.
Export Options
About this article
Cite this article as:
Engen M. R., Marsh S., Van Booven J. D. and McLeod L. H., Ethnic Differences in Pharmacogenetically Relevant Genes, Current Drug Targets 2006; 7 (12) . https://dx.doi.org/10.2174/138945006779025446
DOI https://dx.doi.org/10.2174/138945006779025446 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design Effect of Gender on Main Clinical Chemistry Parameters in Aged Rats
Current Aging Science Contextualizing Genetics for Regional Heart Failure Care
Current Cardiology Reviews Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive Review
Current Pharmaceutical Design Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews The Manzamines as an Example of the Unique Structural Classes Available for the Discovery and Optimization of Infectious Disease Controls Based on Marine Natural Products
Current Pharmaceutical Design Rosuvastatin and Diabetes: When the Evidences Talk
Cardiovascular & Hematological Agents in Medicinal Chemistry ULK1 Plays a Critical Role in AMPK-Mediated Myocardial Autophagy and Contractile Dysfunction following Acute Alcohol Challenge
Current Pharmaceutical Design Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?
Current Vascular Pharmacology Advancement in Microsponge Drug Delivery System: Preparation Methods, Patents and Commercial Utility
Recent Patents on Drug Delivery & Formulation Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Hypoxia in Pre-Eclampsia: Cause or Effect?
Current Women`s Health Reviews Supramolecular Chiro-Biomedical Aspect of β-Blockers in Drug Development
Current Drug Targets Comparative Study of Non-High Density Lipoproteins Cholesterol Level and Lipid Profile in Pre-Diabetic and Diabetic Patients
CNS & Neurological Disorders - Drug Targets Beyond Cholesterol Lowering: Pleiotropic Effects of Bile Acid Binding Resins Against Cardiovascular Disease Risk Factors in Patients with Metabolic Syndrome
Current Vascular Pharmacology Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Inverse Regulation of MMP-9 and MMP-2 in Long-Term Follow-up After Acute Coronary Syndrome: Lack of Correlation with Platelet and Endothelial Cell Activation Markers
Vascular Disease Prevention (Discontinued) Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews